Literature DB >> 19028112

CT-guided needle biopsy: value of on-site cytopathologic evaluation of core specimen touch preparations.

Mei-Hua Tsou1, Shu-Fen Tsai, Kwan-Yee Chan, Cheng-Fang Horng, Ming-Yuan Lee, Ai-Ying Chuang, Ming-Chih Chern.   

Abstract

PURPOSE: To examine the diagnostic effect of immediate on-site cytopathologic evaluation of tissue core touch preparations in computed tomographic (CT)-guided coaxial needle biopsy.
MATERIALS AND METHODS: The authors reviewed the records of 430 patients and included 413 patients with 432 biopsies (210 in the lungs, 222 in other locations). Each time the guiding needle was moved to a new location in the lesion for tissue core procurement with the cutting needle, it represented a new session. Core specimen touch preparations were obtained and immediately evaluated on-site for specimen adequacy and preliminary diagnosis. New sessions were considered and/or executed in the case of inconclusive cytopathologic readings. Each final diagnosis was reached according to the pathology report showing "positive for malignancy," "negative but with a specific diagnosis," or "unclear" for further surgical resection specimen or radiologic follow-up.
RESULTS: The accuracy of on-site cytopathologic examination of touch preparations was 80.6% for the first session and increased to 85.9% and 86.3%, respectively, for the second and third sessions. The corresponding accuracies for biopsy were 88.2%, 93.8%, and 94.9%. The overall accuracy was 97.1% for lesions in the lungs and 92.8% for lesions at other sites. More biopsy sessions were deemed necessary in lesions measuring 2 cm or smaller (P = .0045). During CT-guided lung biopsy, 10 patients (4.8%) had major complications that necessitated chest tube insertion.
CONCLUSIONS: The diagnostic accuracy of CT-guided needle biopsy can be increased through repeated sessions with immediate on-site cytologic evaluation, especially for lesions of 2 cm or smaller and those from nonpulmonary sites.

Entities:  

Mesh:

Year:  2008        PMID: 19028112     DOI: 10.1016/j.jvir.2008.10.011

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  6 in total

Review 1.  [Rapid on-site evaluation (ROSE) in cytological diagnostics of pulmonary and mediastinal diseases].

Authors:  J Wohlschläger; K Darwiche; S Ting; T Hager; L Freitag; K W Schmid; H Kühl; D Theegarten
Journal:  Pathologe       Date:  2012-07       Impact factor: 1.011

2.  Factors influencing the diagnostic yield and accuracy of image-guided percutaneous needle biopsy of pediatric tumors: single-center audit of a 26-year experience.

Authors:  Eléonore Blondiaux; Méryle Laurent; Etienne Audureau; Sabah Boudjemaa; Chiara Sileo; Marion Lenoir; Linda Dainese; Catherine Garel; Aurore Coulomb; Hubert Ducou le Pointe
Journal:  Pediatr Radiol       Date:  2015-11-20

Review 3.  Updates in percutaneous lung biopsy: new indications, techniques and controversies.

Authors:  Jonathan M Lorenz
Journal:  Semin Intervent Radiol       Date:  2012-12       Impact factor: 1.513

4.  Dynamic telecytologic evaluation of imprint cytology samples from CT-guided lung biopsies: a feasibility study.

Authors:  Helmut Prosch; Elisabeth Hoffmann; Klaus Bernhardt; Johann Schalleschak; Ewald Schober; Marcel Rowhani; Michael Weber; Gerhard Mostbeck
Journal:  Eur Radiol       Date:  2011-05-08       Impact factor: 5.315

5.  CT-guided coaxial biopsy of malignant lung lesions: are cores from 20-gauge needle adequate for histologic diagnosis and molecular analysis?

Authors:  Kyongmin S Beck; Tae-Jung Kim; Kyo Young Lee; Young Kyoon Kim; Jin Hyoung Kang; Dae Hee Han
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

6.  Diagnostic efficiency and safety of rapid on-site evaluation combined with CT-guided transthoracic core needle biopsy in suspected lung cancer patients.

Authors:  Ruzetuoheti Yiminniyaze; Xiujuan Zhang; Yuanyuan Zhang; Kun Chen; Chengwei Li; Ning Zhu; Daibing Zhou; Jing Li; Yuhai Zhang; Shengqing Li
Journal:  Cytopathology       Date:  2022-05-10       Impact factor: 1.286

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.